Log in

Relevant bibliographies by topics / Congresses Immunotherapy

Contents

Journal articles
Books
Book chapters
Conference papers

Academic literature on the topic 'Congresses Immunotherapy'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Congresses Immunotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Congresses Immunotherapy"

1

Voronova, Veronika M., Svetlana A. Lebedeva, Marina I. Sekacheva, Gabriel Helmlinger, and Kirill V. Peskov. "Efficacy of radiotherapy vs. The combination of radio- and immunotherapy: a systematic review and meta-analysis." Medical Journal of the Russian Federation 26, no. 1 (June 25, 2020): 67–73. http://dx.doi.org/10.18821/0869-2106-2020-26-1-67-73.

Full text

Abstract:

Introduction and objectives. The combination of radiotherapy and immune checkpoint inhibitors has demonstrated antitumor activity in numerous preclinical studies and is currently being investigated in the clinical setting. This study aims to compare the efficacy of radiotherapy alone (RT) vs. the combination of radio- and immunotherapy (IT-RT) and identify the treatment regimen associated with maximal efficacy by using a meta-analysis. Materials and methods. A systematic literature search was performed using the PubMed database and materials of the key oncology congresses. Studies reporting 1-year overall survival (OS) of patients with brain metastases undergoing IT-RT treatment were included in the analysis. Information about 1-year OS, individual patients characteristics, and treatment regimens for both IT-RT and control RT arms was extracted. Identification of the optimal treatment regimen was performed using a mixed meta-regression modeling approach. Analysis was performed using the R statistical environment (metafoR package). Results. In total, 30 studies were identified, of which 13 reported outcomes for the control RT groups. The analysis revealed that IT inclusion into RT is associated with a significant increase in 1-year OS; given simultaneously, IT and RT demonstrated the highest efficacy with a 1-year OS of 68% (95% confidence interval (CI): 60%75%), followed by a sequential regimen: 1-year OS = 54% (95% CI: 47%61%) and RT alone: 1-year OS = 32% (95% CI: 2539%). Conclusion. The current study demonstrates the superiority of combined IT-RT over RT alone; simultaneous IT and RT treatment is associated with the highest efficacy.

APA, Harvard, Vancouver, ISO, and other styles

2

Maiorano, Brigida Anna, Mauro Francesco Pio Maiorano, Domenica Lorusso, and Evaristo Maiello. "Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives." Cancers 13, no. 17 (September 3, 2021): 4438. http://dx.doi.org/10.3390/cancers13174438.

Full text

Abstract:

Background: Ovarian cancer (OC) represents the eighth most common cancer and the fifth leading cause of cancer-related deaths among the female population. In an advanced setting, chemotherapy represents the first-choice treatment, despite a high recurrence rate. In the last ten years, immunotherapy based on immune checkpoint inhibitors (ICIs) has profoundly modified the therapeutic scenario of many solid tumors. We sought to summarize the main findings regarding the clinical use of ICIs in OC. Methods: We searched PubMed, Embase, and Cochrane Databases, and conference abstracts from international congresses (such as ASCO, ESMO, SGO) for clinical trials, focusing on ICIs both as monotherapy and as combinations in the advanced OC. Results: 20 studies were identified, of which 16 were phase I or II and 4 phase III trials. These trials used ICIs targeting PD1 (nivolumab, pembrolizumab), PD-L1 (avelumab, aterolizumab, durvalumab), and CTLA4 (ipilimumab, tremelimumab). There was no reported improvement in survival, and some trials were terminated early due to toxicity or lack of response. Combining ICIs with chemotherapy, anti-VEGF therapy, or PARP inhibitors improved response rates and survival in spite of a worse safety profile. Conclusions: The identification of biomarkers with a predictive role for ICIs’ efficacy is mandatory. Moreover, genomic and immune profiling of OC might lead to better treatment options and facilitate the design of tailored trials.

APA, Harvard, Vancouver, ISO, and other styles

3

Yekeduz, Emre, Elif Berna Koksoy, Hakan Akbulut, Gungor Utkan, and Yuksel Urun. "A trial-level correlation analysis of progression-free survival as a surrogate for overall survival in the immunotherapy era." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e18580-e18580. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e18580.

Full text

Abstract:

e18580 Background: Progression-free survival (PFS) is accepted as a surrogate endpoint for cancer drugs approval by the Food and Drug Association. In the expanding immunotherapy era, there is no convincing data for reliable surrogacy of PFS. Methods: We systematically searched PubMed and included all phase III trials of ICIs. Besides, we manually included phase III trials of ICIs presented in congresses. Trials including non-metastatic patients and hematologic malignancies were excluded. The primary endpoint was the relationship between treatment effects (i.e., hazard ratio (HR) of PFS and overall survival (OS)). The secondary endpoint was the relationship between the median PFS (mPFS) and median OS (mOS). We also performed subgroup analyses by ICIs subtypes (i.e., anti-programmed death-1 (PD-1) and anti-programmed death ligand-1 (PD-L1)), treatment lines (i.e., the first-line and subsequent treatments), ICI plus CT combination, and ICI monotherapy. To ensure parametric assumptions, we addressed logarithmic conversion to HRs by using log10. We used Pearson’s correlationand weighted linear regression for parametric variables and Spearman’s rank-order correlation for non-parametric variables. We assessed the relationship between variables by using correlation coefficient (r) and coefficient of determination (R2). Results: We included 57 phase III clinical trials with 39,525 patients. A total of 67 outcomes were compared. There was a good correlation between the logarithmic HR of PFS (log HRPFS) and OS (log HROS) (r=0.71, R2=0.50 p<0.001). In subgroup analyses, there was a weak or moderate correlation between the log HRPFS and log HROS in anti-PD-L1, ICI plus CT, and the first-line treatment subgroups (r=0.61, R2=0.38 p=0.004 for anti-PD-L1; r=0.65, R2=0.43 p=0.008 for ICI plus CT; r=0.70, R2=0.49 p<0.001 for the first-line treatment). Conversely, there was a good correlation between the log HRPFS and log HROS in the anti-PD-1, ICI monotherapy, and subsequent treatment line subgroups (r=0.81, R2=0.66 p<0.001 for anti-PD-1; r=0.71, R2=0.51 p<0.001 for ICI monotherapy; r=0.78, R2=0.62 p<0.001 for subsequent treatment line). Correlations between the mPFS and mOS were good or strong in all subgroups. (Table). Conclusions: PFS might be considered a reliable surrogate endpoint for OS, particularly in anti-PD-1 ICIs, ICI monotherapy, and subsequent metastatic cancer treatment lines.[Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

4

Friedman, Claire, and Michael Postow. "Managing Immunotherapy-related Side Effects." Oncology & Hematology Review (US) 11, no. 02 (2015): 143. http://dx.doi.org/10.17925/ohr.2015.11.02.143.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Deja, Adam. "Combination of radiation and immunotherapy – current scientific research." Letters in Oncology Science 15, no. 3 (September 11, 2018): 102–6. http://dx.doi.org/10.21641/los.15.3.86.

Full text

Abstract:

In recent years, it has been noted that the combination of radiation and immunotherapy is more benefitial than both modalities used separately. The interactions between immune checkpoint inhibitors and high-dose radiotherapy are curently an important topic of ongoing scientific trials. This review highlights some of the presented papers during the ESTRO 37 congress in 2018.

APA, Harvard, Vancouver, ISO, and other styles

6

Ascierto, Paolo A., Carlo Bifulco, Jerome Galon, Claus Garbe, Samir N. Khleif, Jennifer McQuade, Kunle Odunsi, et al. "The Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019." Journal for ImmunoTherapy of Cancer 8, no. 2 (August 2020): e000921. http://dx.doi.org/10.1136/jitc-2020-000921.

Full text

Abstract:

As part of the 2019 Immunotherapy Bridge congress (December 4–5, Naples, Italy), the Great Debate session featured counterpoint views from leading experts on six topical issues in immunotherapy today. These were the use of chimeric antigen receptor T cell therapy in solid tumors, whether the Immunoscore should be more widely used in clinical practice, whether antibody-dependent cellular cytotoxicity is important in the mode of action of anticytotoxic T-lymphocyte-associated protein 4 antibodies, whether the brain is immunologically unique or just another organ, the role of microbiome versus nutrition in affecting responses to immunotherapy, and whether chemotherapy is immunostimulatory or immunosuppressive. Discussion of these important topics are summarized in this report.

APA, Harvard, Vancouver, ISO, and other styles

7

Kurstak, Edouard. "Tenth World Congress on Vaccines, Immunisation and Immunotherapy." Human Vaccines & Immunotherapeutics 13, no. 2 (December 7, 2016): 253–54. http://dx.doi.org/10.1080/21645515.2017.1264838.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kurstak, Edouard. "Eighth World Congress on Vaccines, Immunisation and Immunotherapy." Human Vaccines & Immunotherapeutics 9, no. 3 (March 18, 2013): 449. http://dx.doi.org/10.4161/hv.23219.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kurstak, Edouard. "Ninth World Congress on Vaccines, Immunisation and Immunotherapy." Human Vaccines & Immunotherapeutics 11, no. 1 (January 2015): 3–4. http://dx.doi.org/10.4161/hv.36386.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Kurstak, Edouard. "Preface: Seventh World Congress on Vaccines, Immunisation and Immunotherapy." Human Vaccines 7, sup1 (January 2011): 1. http://dx.doi.org/10.4161/hv.7.0.14904.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Congresses Immunotherapy"

1

Italy) International Cancer Vaccine Symposium (7th 2012 Florence. The renaissance of cancer immunotherapy. Edited by Finn Olivera J and Schuler G. (Gerold). Hoboken, NJ: Published on behalf of the New York Academy of Sciences by Wiley Subscription Services, Inc., 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

International Workshop on Monoclonal Antibodies and Breast Cancer (3rd 1988 San Francisco, Calif.). Breast cancer immunodiagnosis and immunotherapy. New York: Plenum Press, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

International, Conference on Labeled Antibodies (8th 1985 Tokyo Japan). Cellular, molecular, and genetic approaches to immunodiagnosis and immunotherapy. Basel: Karger, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Motomichi, Torisu, and Yoshida Takeshi, eds. New horizons of tumor immunotherapy: Proceedings of the International Symposium on New Horizons of Tumor Immunotherapy, held in Fukuoka, Japan, 30 November-2 December 1988. Amsterdam: Excerpta Medica, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Symposium in Immunology (4th 1994 Heidelberg, Germany). Symposium in immunology IV: Allergic diseases. Berlin: Springer-Verlag, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

International, Symposium on Cellular Immunotherapy of Cancer (1986 Racine Wis ). Cellular immunotherapy of cancer: Proceedings of the International Symposium on Cellular Immunotherapy of Cancer, held at Racine, Wisconsin, October 30-November 1, 1986. New York: Liss, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

International Symposium on Cellular Immunotherapy of Cancer (1986 Racine, Wis.). Cellular immunotherapy of cancer: Proceedings of the International Symposium on Cellular Immunotherapy of Cancer, held at Racine, Wisconsin, October 30-November 1, 1986. Edited by Truitt Robert L. ed, Gale Robert Peter ed, and Bortin Mortimer M. ed. New York: Liss, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

International, Symposium on Cellular Immunotherapy of Cancer (1986 Racine Wis ). Cellular immunotherapy of cancer: Proceedings of the International Symposium on Cellular Immunotherapy of Cancer, held at Racine, Wisconsin, Oct. 30 - Nov. 1, 1986. New York: Liss, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

International, Paul-Ehrlich-Seminar (12th 2008 Bad Homburg vor der Höhe Germany). Regulatory control and standardization of allergenic extracts: 12th International Paul-Ehrlich-Seminar, September 24 - 27, 2008, Hotel Steigenberger, Bad Homburg, Bad Homburg, Germany. Wiesbaden: Chmielorz, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

International Symposium on the Present Status of Non-Toxic Concepts in Cancer (1986 European Academy, Nonnweiler, Germany). Present status of non-toxic concepts in cancer. Edited by Klippel K. -F and Macher E. Basel: Karger, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Congresses Immunotherapy"

1

Riccardo, F., V. Rolih, and F. Cavallo. "Animal Models for Translational Cancer Immunotherapy Studies." In 1st World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies, 391–94. Singapore: Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-287-817-5_85.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Negrier, S., A. Mercatello, M. Bret, P. Thiesse, R. Oskam, C. R. Franks, J. F. Moskovtchenko, and T. Philip. "Immunotherapy in metastatic renal cell cancer. The Lyon’s experience on 100 patients." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 113–14. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_30.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Swann, James. "Novel immunotherapy." In BSAVA Congress Proceedings 2019, 173–74. British Small Animal Veterinary Association, 2019. http://dx.doi.org/10.22233/9781910443699.25.3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Nuttall, Tim. "Allergy testing and allergen specific immunotherapy – is it really worth doing any more?" In BSAVA Congress Proceedings 2018, 153. British Small Animal Veterinary Association, 2018. http://dx.doi.org/10.22233/9781910443590.19.3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Congresses Immunotherapy"

1

Zarogoulidis, Pavlos, Dora Tsiouda, Anastasios Kallianos, Aggeliki Rapti, Chrysanthi Sardeli, Haidong Huang, Wolfgang Hohenforst-Schmidt, Georgia Trakada, and Konstantinos Sapalidis. "Inhaled immunotherapy for lung cancer? Certainly possible." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa2220.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Amira, Sellami, Moetamri Zied, Mhamdi Samira, Dabboussi Selsabil, Aichaouia Chiraz, Khadhraoui Mohsen, and Echikh Rzaiek. "Tolerance of ultra-rush immunotherapy in children." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa4023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Alves, Adelaide, Inês Sucena, Margarida Dias, Daniel Coutinho, Eloisa Silva, Telma Costa, Sara Conde, Ana Barroso, and Sérgio Campainha. "Eosinophilia in lung cancer patients treated with immunotherapy." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa4664.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Barata, Margarida, Gabriela Santos, Helena Grumete, Miguel Lopes, Dolores Canário, and José Duarte. "Predictors of immunotherapy induced immune-related adverse events." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa4665.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Tataurshchikova, Nataly. "Sublingual immunotherapy among patients, suffering from allergic rhinitis." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa625.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Alves, Adelaide, Inês Sucena, Margarida Dias, Daniel Coutinho, Telma Costa, Eloisa Silva, Sara Conde, Sérgio Campainha, and Ana Barroso. "Impact of antibiotics on immunotherapy response in lung cancer patients." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa371.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Zheng, Peiyan, and Baoqing Sun. "Metabolomic profiling of serum during allergy immunotherapy in asthmatic children." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.oa1479.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Hoshino, Makoto, Kenta Akitsu, Kengo Kubota, and Junichi Ohtawa. "House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.236.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kanai, Osamu, Kohei Fujita, Misato Okamura, Kanna Horimoto, Masayuki Hashimoto, Koichi Nakatani, Satoru Sawai, and Tadashi Mio. "Association between cyclooxygenase inhibitor use and efficacy of immunotherapy: a retrospective study." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.1658.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Lazarenko, Lyudmila, Galina Sergeeva, and Elena Lazutkina. "Allergen immunotherapy modulates pro- and antioxidant status patients with bronchial asthma." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa3540.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!